查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929664

Quetiapine喹硫平片市場：依產品、適應症、劑型及通路分類，全球預測（2026-2032年）

Quetiapine Fumarate Tablets Market by Product Type, Indication, Dosage Form, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Quetiapine硫平片市場價值將達到 24.7 億美元，到 2026 年將成長至 26.5 億美元，到 2032 年將達到 39.2 億美元，複合年成長率為 6.77%。

關鍵市場統計數據
基準年 2025 24.7億美元
預計年份：2026年 26.5億美元
預測年份 2032 39.2億美元
複合年成長率 (%) 6.77%

本概要全面介紹了Quetiapine喹硫平片在精神科治療中的臨床應用、治療動力學和治療定位。

Quetiapine喹硫平片在精神科的多種治療適應症中佔據穩固的地位，涵蓋從急性期治療到維持治療的各個階段。本導言概述了速釋和緩釋製劑的臨床效用，重點介紹了常規實踐中的關鍵給藥優勢，並闡明了Quetiapine在情緒障礙和精神病性障礙治療流程中的地位。此外，本導言也闡述了製劑和給藥方案的選擇如何影響處方醫師的偏好、病患的用藥依從性以及醫院的用藥清單。

分析近期臨床、監管和商業性轉折點如何重塑Quetiapine喹硫平片的處方行為和生命週期策略

Quetiapine喹硫平片的市場環境因臨床證據的不斷改進、製劑創新以及醫療服務模式的變革而轉變。近期臨床研究明確了不同製劑的耐受性，並加深了對長期安全性的理解，從而促使處方指南更新，並在那些以提高用藥依從性和減少副作用為優先考慮的患者群體中推廣使用緩釋製劑。同時，非專利藥製劑科學和監管途徑的進步也加劇了市場競爭，競爭焦點集中在生物等效性、輔料特性以及新型緩釋技術等。

評估2025年美國關稅趨勢對Quetiapine硫平片生產籌資策略與供應鏈韌性的累積影響

美國2025年實施的關稅政策變化對Quetiapine喹硫平錠劑所用藥物原料和製劑的生產和分銷產生了重大影響。某些原料和中間體成分關稅的提高加劇了投入成本壓力，促使製造商重新評估其籌資策略並整合其供應基地。這些變化促使人們重新評估區域製造地，並加快了關於近岸外包和雙重採購的討論，以降低長期海關相關中斷的風險。

詳細的細分分析揭示了適應症分佈、劑量強度、產品類型和患者人口統計動態對使用趨勢和分銷管道動態的影響。

Quetiapine喹硫平片的市場區隔分析揭示了臨床適應症、分銷管道、劑型、劑量強度、產品類型和患者年齡層等因素的不同需求促進因素，這些因素對產品開發和商業化均具有獨特的影響。在臨床適應症方面，雙極性情感障礙躁症主要針對雙極I型和II型症狀進行評估，思覺失調症則涵蓋急性期和慢性期，而重度憂鬱症則主要評估其輔助性治療治療效果。這些臨床亞群會影響治療持續時間、給藥模式以及緩釋製劑與速釋製劑的相對吸引力。

區域趨勢和醫療保健生態系統的差異正在導致醫療服務取得和使用模式的差異。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區Quetiapine喹硫平片的取得模式、監管路徑和商業性策略有顯著影響。每個區域在支付環境、臨床實踐和供應鏈考量方面都存在顯著差異。在美洲，完善的法規結構以及成熟的醫院和零售通路推動了可預測的市場接受度曲線，而處方箋談判和衛生技術評估則影響著品牌藥和非專利藥的共存。該地區的銷售管道組合兼顧醫院採購和零售藥局網路，而線上藥局的興起正在改變最後一公里配送模式，並提升病患的便利性。

針對領先品牌藥和非專利生產商的競爭情報，重點分析了Quetiapine喹硫平片的研發重點、配方差異化和商業化策略。

品牌藥和非專利生產商之間的競爭定位主要體現在配方創新、生命週期管理和通路特定的商業策略。品牌藥生產商為了維持其品牌地位，往往會投資於配方改良，透過緩釋技術和改善耐受性來擴大專利保護帶來的差異化優勢，同時保留傳統處方醫生熟悉的原始配方。非專利藥生產商則專注於證明其具有良好的生物等效性、確保穩定的供應，並與大型採購機構和連鎖藥局協商優先供貨權。

為行業領導者提供策略建議，以加強產品系列、最佳化供應鏈，並使臨床開發與支付方和處方醫生的期望保持一致。

產業領導者應採取多管齊下的策略，將產品創新與穩健的供應鏈以及針對不同管道和患者群體設計的商業模式相結合。優先開發緩釋製劑和配方改良策略，以應對實際應用中的依從性和耐受性挑戰，同時確保已通過核准非專利處方藥具備完善的生物等效性，並支持品牌藥和非品牌藥之間的無縫過渡。近期戰術性措施包括：實現關鍵輔料和中間體供應商多元化、簽訂緊急生產協議以及發展區域生產能力，以減輕關稅和貿易政策的影響。

一項透明的調查方法，詳細說明了用於得出有關Quetiapine喹硫平片研究結果的一級和二級研究、證據檢驗驗證和品管。

這些研究結果所依據的調查方法結合了關鍵相關人員的對話、嚴謹的二手證據審查和系統性的綜合分析，從而得出切實可行的可靠結論。主要研究包括對精神科各專科的臨床醫生、醫院系統的採購和處方決策者以及負責生產和分銷的商業領導者進行結構化訪談。這些訪談提供了對處方動機、分銷管道動態和供應鏈脆弱性的定性理解。

綜合臨床、商業性和政策方面的考慮，為相關人員就Quetiapine喹硫平片做出策略決策提供最終的綜合分析。

這項綜合分析整合了臨床、商業性和政策層面，全面展現了Quetiapine喹硫平片的策略環境。臨床上，製劑選擇和劑量強度仍然是平衡耐受性和實現治療目標的關鍵，而針對特異性年齡層患者的用藥情況在編寫附加檔和患者支持材料時需要格外注意。商業性，新品牌製劑和學名藥的競爭，以及不斷變化的經銷管道和支付方的期望，都要求制定靈活的產品系列和通路策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Quetiapine喹硫平片市場（依產品類型分類）

  • 品牌產品
    • 原始配方
    • 重新配方
  • 非專利的
    • 核准的非專利
    • 無品牌非專利

第9章Quetiapine喹硫平片市場依適應症分類

  • 雙極性情感障礙中的躁狂狀態
    • 1型雙極性情感障礙
    • 雙極性情感障礙II型
  • 重度憂鬱症
  • 思覺失調症
    • 急性
    • 慢性的

第10章Quetiapine硫平片市場按劑型分類

  • 緩釋
  • 快速起效

第11章Quetiapine硫平片市場（依通路分類）

  • 醫院藥房
    • 非教學醫院
    • 教學醫院
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第12章Quetiapine喹硫平片市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章Quetiapine硫平片市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國Quetiapine硫平片市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國Quetiapine硫平片市場

第16章 中國Quetiapine硫平片市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accord Healthcare Limited
  • Alkem Laboratories Ltd.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Cheplapharm Arzneimittel GmbH
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Hetero Labs Ltd.
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Luye Pharma Group Limited
  • Pharmathen Investments Group
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • Viatris Inc.
Product Code: MRR-0A380695187C

The Quetiapine Fumarate Tablets Market was valued at USD 2.47 billion in 2025 and is projected to grow to USD 2.65 billion in 2026, with a CAGR of 6.77%, reaching USD 3.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.47 billion
Estimated Year [2026] USD 2.65 billion
Forecast Year [2032] USD 3.92 billion
CAGR (%) 6.77%

Comprehensive executive overview introducing clinical applications treatment dynamics and therapeutic positioning of quetiapine fumarate tablets across psychiatric care

Quetiapine fumarate tablets occupy an established role across several therapeutic indications in psychiatry, encompassing acute and maintenance treatment regimens. This introduction frames the clinical utility of immediate-release and extended-release formulations, highlights key dosing strengths in routine practice, and situates quetiapine's therapeutic positioning relative to treatment algorithms for mood and psychotic disorders. It also underscores how formulation choices and strength availability influence prescriber preference, patient adherence, and hospital formularies.

The report begins by contextualizing quetiapine's pharmacologic profile, covering its receptor activity and tolerability considerations that inform risk-benefit discussions between clinicians and payers. Regulatory approvals across major jurisdictions and label differentiations for bipolar mania, major depressive disorder adjunctive therapy, and schizophrenia reflect nuanced clinical pathways; understanding these distinctions is foundational for strategic planning. Finally, the introduction sets expectations for subsequent sections by outlining the scope of analysis, the segmentation lenses applied to utilization and distribution, and the strategic imperatives for manufacturers and health systems seeking to optimize therapeutic outcomes while navigating commercial pressures.

Analysis of recent clinical regulatory and commercial inflection points reshaping prescribing behavior and lifecycle strategies for quetiapine fumarate tablets

The landscape for quetiapine fumarate tablets has evolved through a convergence of clinical evidence refinement, formulation innovation, and shifting healthcare delivery models. Recent clinical research has clarified comparative tolerability profiles and expanded understanding of long-term safety considerations, prompting updates in prescribing guidance and influencing the adoption of extended-release formulations in populations where adherence and side-effect mitigation are priorities. Concurrently, advances in generic formulation science and regulatory pathways have increased competition focused on bioequivalence, excipient profiles, and novel controlled-release technologies.

Commercially, payers are intensifying scrutiny of formulary placement criteria and real-world outcomes, which in turn pressures manufacturers to demonstrate economic as well as clinical value. Distribution channel dynamics have shifted with the growth of online pharmacies and integrated health system procurement, creating both risk and opportunity for manufacturers that can align channel strategy with patient access goals. Additionally, lifecycle management through reformulation, authorized generics, and targeted indication strategies has become a core differentiator for originator companies seeking to retain clinical relevance. Finally, the intersection of digital health tools for monitoring adherence and regulatory emphasis on patient safety has opened new avenues for product differentiation and provider engagement.

Evaluation of the cumulative consequences of United States tariff developments in 2025 on manufacturing sourcing strategies and supply chain resilience for quetiapine fumarate tablets

Developments in United States tariff policy during 2025 have had material implications for the production and distribution of pharmaceutical ingredients and finished dosage forms used in quetiapine fumarate tablets. Increased duties on certain raw materials and intermediate components have elevated input cost pressure, encouraging manufacturers to reassess sourcing strategies and consolidate supplier bases. These shifts have prompted a reassessment of regional manufacturing footprints and accelerated conversations about nearshoring and dual-sourcing to mitigate the risk of prolonged customs-related disruptions.

As a consequence, contract negotiations with suppliers and third-party manufacturers have increasingly embedded clauses addressing tariff pass-through, inventory commitments, and force majeure events tied to trade policy changes. Payers and procurement teams have responded by refining inventory management protocols and by seeking contractual protections against sudden cost inflation. At the same time, regulatory compliance and customs clearance complexity have lengthened lead times for certain cross-border shipments, nudging supply chain planners to build buffer stock for critical strengths and to validate alternate distribution pathways.

Smaller generic manufacturers with thin margins have experienced heightened pressure to optimize cost structures, which in some instances has accelerated consolidation or shifted production toward higher-volume, lower-complexity dosage forms. Conversely, larger manufacturers with broader global networks have leveraged scale to absorb some tariff impact while renegotiating commercial terms with distributors and large pharmacy chains. Ultimately, the tariff environment has amplified the strategic emphasis on resilient sourcing, contractual flexibility, and proactive engagement with customs and trade specialists to preserve continuity of supply and manage unit economics without compromising patient access.

Granular segmentation insights revealing how indication distribution dosage form strength product type and patient age stratifications influence utilization and channel dynamics

Segmentation analysis of quetiapine fumarate tablets demonstrates differentiated drivers of demand across clinical indication, distribution channel, dosage form, strength, product type, and patient age group, each with specific implications for product development and commercialization. Within clinical indication, bipolar mania is examined with attention to Bipolar I and Bipolar II presentations, while schizophrenia is considered across acute and chronic episodes; major depressive disorder is evaluated primarily in its adjunctive role. These clinical subpopulations influence treatment duration, dosing patterns, and the relative attractiveness of extended-release versus immediate-release formulations.

Distribution channel segmentation distinguishes between hospital pharmacy environments and retail settings, with hospital pharmacy analysis differentiating non-teaching hospitals from teaching hospitals and retail pharmacy analysis separating chain pharmacy operations from independent outlets; online pharmacies overlay both segments and are changing fulfillment models and patient access dynamics. Dosage form segmentation contrasts extended-release and immediate-release products, where extended-release options play a role in adherence and dosing convenience, and immediate-release forms remain relevant for titration and acute symptom management.

Strength-related segmentation divides offerings into high strength and low strength categories; high strength forms include 200 mg and 300 mg tablets while low strength forms cover 100 mg, 25 mg, and 50 mg options, and these strength tiers map to distinct prescribing patterns and inpatient versus outpatient utilization. Product type segmentation contrasts branded products-broken down into original formulation and reformulation strategies-with generic products that include authorized generics and unbranded generics, each presenting different channel dynamics and pricing strategies. Patient age group segmentation differentiates adults from geriatrics and pediatrics, with adults further split into 18 to 44 and 45 to 64 cohorts, geriatrics into 65 to 74 and 75 and above, and pediatrics into 0 to 12 and 13 to 17 bands; these age strata affect dosing, tolerability considerations, and regulatory labeling requirements. Taken together, these segmentation lenses reveal that manufacturers must tailor product portfolios, clinical communications, and distribution approaches to the interplay of indication complexity, setting of care, formulation attributes, strength availability, and demographic factors to optimize therapeutic reach and operational efficiency.

Regional dynamics and healthcare ecosystem contrasts across the Americas Europe Middle East and Africa and Asia Pacific that are driving differential access and adoption patterns

Regional dynamics exert powerful influence on access patterns, regulatory pathways, and commercial approaches for quetiapine fumarate tablets across the Americas, Europe Middle East and Africa, and Asia-Pacific, each presenting distinct payer environments, clinical practices, and supply chain considerations. In the Americas, established regulatory frameworks and mature hospital and retail channels drive predictable adoption curves, with formulary negotiations and health technology assessment considerations shaping how branded and generic options coexist. The channel mix in this region emphasizes both hospital procurement and retail pharmacy networks, with online pharmacy growth altering last-mile distribution and patient convenience.

Across Europe, Middle East and Africa, heterogeneity in regulatory regimes and reimbursement systems results in variation in label interpretations, prescribing norms, and price regulation. Teaching hospitals and national health systems in many jurisdictions play an outsized role in guideline adoption, while private sectors and retail pharmacies respond to local reimbursement mechanisms that can affect access to higher-strength or extended-release formulations. The Asia-Pacific region exhibits dynamic manufacturing capacity coupled with diverse healthcare delivery models; several countries in the region are important production hubs for active ingredients and finished dose forms, and local distribution channels range from integrated hospital networks to rapidly expanding e-commerce pharmacies. Regional strategies therefore must account for differentiated regulatory timelines, supply chain footprints, and payer negotiation levers, with cross-border regulatory harmonization and trade policies further influencing sourcing and commercial tactics.

Competitive intelligence on leading originator and generic manufacturers highlighting R and D focus formulation differentiation and commercialization strategies within quetiapine fumarate tablets

Competitive positioning among originator and generic players centers on formulation innovation, lifecycle management, and channel-specific commercial execution. Originator manufacturers that retain branded positions often invest in reformulation to extend patent-protected differentiation through extended-release technologies or improved tolerability profiles, while also maintaining original formulations to serve legacy prescriber familiarity. Generic manufacturers focus on demonstrating robust bioequivalence, ensuring consistent supply, and negotiating preferred placements with large procurement entities and chain pharmacies.

Strategic alliances with contract manufacturers and specialty packaging providers are increasingly common, enabling flexibility in production scale and formulation complexity. Investment in real-world evidence programs and post-marketing safety studies has become a key tactic for both originator and generic companies to support formulary discussions and clinician confidence. Additionally, differentiated commercial models-such as risk-sharing arrangements with payers, value-based contracting pilots, and patient support services-are being piloted to bolster product uptake and adherence. Companies that combine manufacturing reliability, distribution reach across hospital and retail channels, and clinical support capabilities are best positioned to navigate payer pressures and prescriber expectations while preserving margins and sustaining long-term relationships with healthcare systems.

Strategic recommendations for industry leaders to strengthen product portfolios optimize supply chains and align clinical development with payer and prescriber expectations

Industry leaders should adopt a multi-pronged strategy that aligns product innovation with resilient supply chains and targeted commercial models designed for diverse channels and patient segments. Prioritize development of extended-release and reformulation strategies that address adherence and tolerability gaps identified in real-world practice, while ensuring robust bioequivalence packages for authorized generics to support seamless transitions between branded and unbranded offerings. Near-term tactical steps include diversifying supplier bases for key excipients and intermediates, establishing contingency manufacturing agreements, and cultivating regional production capacity to mitigate tariff and trade-policy exposure.

Commercially, strengthen engagement with hospital formularies and integrated delivery networks by offering data packages that address clinical outcomes, safety profiles, and health-economic considerations. Expand digital and telepharmacy collaborations to capture the growing share of outpatient fulfillment and to support patient adherence programs. For pricing and contracting, explore outcome-linked arrangements and transparent rebate structures that align incentives with payer priorities while preserving access to higher-strength and extended-release products. Finally, invest in targeted lifecycle management activities-such as indication-seeking supplements, pediatric formulation work, and comparative tolerability studies-to sustain clinical relevance and to open pathways for differentiated reimbursement.

Transparent research methodology detailing primary and secondary approaches evidence triangulation and quality controls employed to derive insights into quetiapine fumarate tablets

The research methodology underpinning these insights integrates primary stakeholder engagement with rigorous secondary evidence review and structured synthesis to ensure actionable and reliable conclusions. Primary research included structured interviews with clinicians across psychiatry subspecialties, procurement and formulary decision-makers within hospital systems, and commercial leaders responsible for manufacturing and distribution. These conversations informed qualitative understanding of prescribing drivers, channel dynamics, and supply chain vulnerabilities.

Secondary research comprised review of regulatory labeling across jurisdictions, evaluation of clinical literature on efficacy and tolerability of immediate-release and extended-release quetiapine formulations, and analysis of public procurement and trade-policy documents to assess implications for sourcing. Data triangulation blended interview findings, regulatory and clinical evidence, and supply chain intelligence to validate assertions and to identify convergent themes. Methodological controls included cross-validation of interview responses, documentation of source provenance, and transparency around areas where evidence is emerging or where heterogeneity across geographies limits generalizability. Where relevant, scenario planning techniques were used to explore potential responses to tariff shifts and to assess operational levers available to manufacturers and distributors.

Concluding synthesis that integrates clinical commercial and policy considerations to inform strategic decision making for stakeholders engaged with quetiapine fumarate tablets

This synthesis integrates clinical, commercial, and policy dimensions to present a coherent view of the strategic landscape for quetiapine fumarate tablets. Clinically, formulation choice and dosing strength remain central to achieving therapeutic goals while balancing tolerability, and age-specific considerations require careful attention when developing labeling and patient support materials. Commercially, competition between branded reformulations and generics, combined with evolving distribution channels and payer expectations, necessitates agile portfolio and channel strategies.

Operationally, supply chain resilience and contractual flexibility have moved to the forefront as trade-policy developments and tariff changes impose new cost and lead-time considerations. Companies that balance investment in formulation differentiation with operational excellence in sourcing and distribution will be better positioned to maintain access and to support long-term patient outcomes. Looking ahead, coordinated activities across R&D, regulatory, manufacturing, and commercial teams will be crucial to translate clinical insights into sustainable products that meet the requirements of diverse healthcare systems and patient populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Quetiapine Fumarate Tablets Market, by Product Type

  • 8.1. Branded
    • 8.1.1. Original Formulation
    • 8.1.2. Reformulation
  • 8.2. Generic
    • 8.2.1. Authorized Generic
    • 8.2.2. Unbranded Generic

9. Quetiapine Fumarate Tablets Market, by Indication

  • 9.1. Bipolar Mania
    • 9.1.1. Bipolar I
    • 9.1.2. Bipolar II
  • 9.2. Major Depressive Disorder
  • 9.3. Schizophrenia
    • 9.3.1. Acute
    • 9.3.2. Chronic

10. Quetiapine Fumarate Tablets Market, by Dosage Form

  • 10.1. Extended Release
  • 10.2. Immediate Release

11. Quetiapine Fumarate Tablets Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
    • 11.1.1. Non-Teaching Hospital
    • 11.1.2. Teaching Hospital
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Quetiapine Fumarate Tablets Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Quetiapine Fumarate Tablets Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Quetiapine Fumarate Tablets Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Quetiapine Fumarate Tablets Market

16. China Quetiapine Fumarate Tablets Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accord Healthcare Limited
  • 17.6. Alkem Laboratories Ltd.
  • 17.7. AstraZeneca PLC
  • 17.8. Aurobindo Pharma Limited
  • 17.9. Cheplapharm Arzneimittel GmbH
  • 17.10. Cipla Limited
  • 17.11. Dr. Reddy's Laboratories Ltd.
  • 17.12. Hetero Labs Ltd.
  • 17.13. Intas Pharmaceuticals Ltd.
  • 17.14. Lupin Limited
  • 17.15. Luye Pharma Group Limited
  • 17.16. Pharmathen Investments Group
  • 17.17. Sandoz International GmbH
  • 17.18. Sun Pharmaceutical Industries Limited
  • 17.19. Teva Pharmaceutical Industries Ltd.
  • 17.20. Torrent Pharmaceuticals Limited
  • 17.21. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ORIGINAL FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ORIGINAL FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ORIGINAL FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REFORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REFORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REFORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY AUTHORIZED GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY AUTHORIZED GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY AUTHORIZED GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY UNBRANDED GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY UNBRANDED GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY UNBRANDED GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ACUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY NON-TEACHING HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY NON-TEACHING HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY NON-TEACHING HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY TEACHING HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY TEACHING HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY TEACHING HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 182. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 183. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 185. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 186. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 187. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 215. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 216. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 218. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 219. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 220. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 226. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 227. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 229. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 230. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 231. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)